INSULET CORP

PODD Nasdaq CIK: 0001145197

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 100 NAGOG PARK, ACTON, MA, 01720
Mailing Address 100 NAGOG PARK, ACTON, MA, 01720
Phone 978-600-7000
Fiscal Year End 1231
EIN 043523891

Financial Overview

FY2025

$418.30M
Net Income
$3.19B
Total Assets
$1.88B
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
8-K Current report of material events March 4, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC

Annual Reports

10-K February 18, 2026
  • Insulet achieved robust growth in 2025, driven by the widespread adoption of its Omnipod 5 Automated Insulin Delivery System.
  • Total sales soared 23% to $2.85 billion, with net income reaching $550 million and diluted EPS of approximately $8.00.
View Analysis

Material Events

8-K Legal Issue March 12, 2026
Medium Impact
  • Voluntary medical device correction, not a recall, for Omnipod DASH® Insulin Management System.
  • Insulet reaffirmed its financial guidance despite anticipated costs related to the correction.
View Analysis

Insider Trading

STRONG BUY 4 insiders 4 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.